MicroRNA‑9‑5p increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by downregulating high mobility group A2 expression

Zheng,Huizhe; Yan,Bin; Wu,Qi; Zhang,Jingli

doi:10.3892/ol.2021.12496

MicroRNA‑9‑5p increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by downregulating high mobility group A2 expression

Authors:
- Huizhe Zheng
- Bin Yan
- Qi Wu
- Jingli Zhang
View Affiliations

Affiliations: Department of Pathology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China, Department of Rheumatology and Immunology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China
Published online on: January 26, 2021 https://doi.org/10.3892/ol.2021.12496
Article Number: 235
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy drug 5‑fluorouracil (5‑FU) is the first‑line treatment for colorectal cancer (CRC); however, 5‑FU resistance decreases CRC therapeutic efficiency. A previous study revealed that microRNA (miR)‑9‑5p serves an antitumor effect in CRC. However, the effect of miR‑9‑5p in CRC chemoresistance remains unknown. In the present study, two CRC cell lines, including HT‑29 and HCT‑116 cells, were used to investigate the impact of miR‑9‑5p in overcoming 5‑FU resistance. The results revealed that treatment with 5‑FU decreased CRC cell viability and upregulated miR‑9‑5p expression in both CRC cells. Knockdown of miR‑9‑5p decreased HCT‑116 cell sensitivity to 5‑FU and inhibited apoptosis. By contrast, miR‑9‑5p overexpression enhanced the sensitivity of HT‑29 cells to 5‑FU and induced apoptosis. Additionally, it was confirmed that miR‑9‑5p directly targeted high mobility group A2 (HMGA2). HMGA2 overexpression reversed miR‑9‑5p‑induced HT‑29 apoptosis. The present study indicated that miR‑9‑5p enhanced the sensitivity of CRC cells to 5‑FU via downregulating HMGA2 expression.

View Figures

View References

1	Pisano A, Griñan-Lison C, Farace C, Fiorito G, Fenu G, Jiménez G, Scognamillo F, Peña-Martin J, Naccarati A, Pröll J, et al: The inhibitory role of miR-486-5p on CSC phenotype has diagnostic and prognostic potential in colorectal cancer. Cancers (Basel). 12:34322020. View Article : Google Scholar
2	Giuliani J and Bonetti A: The pharmacological costs of first-line therapies in unselected patients with advanced colorectal cancer: A review of published phase III trials. Clin Colorectal Cancer. 15:277–284. 2016. View Article : Google Scholar : PubMed/NCBI
3	Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, Yang Q, Zhang T and Ma H: 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol. 143:419–431. 2017. View Article : Google Scholar : PubMed/NCBI
4	Wu C, Bardes EE, Jegga AG and Aronow BJ: ToppMiR: Ranking microRNAs and their mRNA targets based on biological functions and context. Nucleic Acids Res. 42((Web Server Issue)): W107–W113. 2014. View Article : Google Scholar : PubMed/NCBI
5	Berindan-Neagoe I, Monroig Pdel C, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhao L, Shan Y, Liu B, Li Y and Jia L: Retraction Note: Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML. Cell Death Dis. 11:1212020. View Article : Google Scholar : PubMed/NCBI
7	Si W, Shen J, Du C, Chen D, Gu X, Li C, Yao M, Pan J, Cheng J, Jiang D, et al: A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance. Cell Death Differ. 25:406–420. 2018. View Article : Google Scholar : PubMed/NCBI
8	Wang B, Lu FY, Shi RH, Feng YD, Zhao XD, Lu ZP, Xiao L, Zhou GQ, Qiu JM and Cheng CE: miR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of Pgp. Am J Cancer Res. 8:2518–2527. 2018.PubMed/NCBI
9	Bao Y, Zhang Y, Lu Y, Guo H, Dong Z, Chen Q, Zhang X, Shen W, Chen W and Wang X: Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. Int J Biol Sci. 16:827–837. 2020. View Article : Google Scholar : PubMed/NCBI
10	Meng Q, Xiang L, Fu J, Chu X, Wang C and Yan B: Transcriptome profiling reveals miR-9-3p as a novel tumor suppressor in gastric cancer. Oncotarget. 8:37321–37331. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhu B, Xi X, Liu Q, Cheng Y and Yang H: miR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4. Am J Transl Res. 11:3384–3397. 2019.PubMed/NCBI
12	Xiong WC, Han N, Ping GF, Zheng PF, Feng HL, Qin L and He P: microRNA-9 functions as a tumor suppressor in colorectal cancer by targeting CXCR4. Int J Clin Exp Pathol. 11:526–536. 2018.PubMed/NCBI
13	Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA and Skotheim RI: miR-9, −31, and −182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia. 14:868–879. 2012. View Article : Google Scholar : PubMed/NCBI
14	Park YR, Lee ST, Kim SL, Liu YC, Lee MR, Shin JH, Seo SY, Kim SH, Kim IH, Lee SO and Kim SW: MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. Int J Oncol. 48:2135–2143. 2016. View Article : Google Scholar : PubMed/NCBI
15	Borrmann L, Schwanbeck R, Heyduk T, Seebeck B, Rogalla P, Bullerdiek J and Wiśniewski JR: High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res. 31:6841–6851. 2003. View Article : Google Scholar : PubMed/NCBI
16	Gao X, Dai M, Li Q, Wang Z, Lu Y and Song Z: HMGA2 regulates lung cancer proliferation and metastasis. Thorac Cancer. 8:501–510. 2017. View Article : Google Scholar : PubMed/NCBI
17	Mansoori B, Mohammadi A, Asadzadeh Z, Shirjang S, Minouei M, Abedi Gaballu F, Shajari N, Kazemi T, Gjerstorff MF, Duijf PHG and Baradaran B: HMGA2 and Bach-1 cooperate to promote breast cancer cell malignancy. J Cell Physiol. 234:17714–17726. 2019. View Article : Google Scholar : PubMed/NCBI
18	Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S, et al: Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 17:2570–2580. 2011. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z and You T: HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett. 355:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
20	Xu X, Wang Y, Deng H, Liu C, Wu J and Lai M: HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway. Oncotarget. 9:9963–9974. 2018. View Article : Google Scholar : PubMed/NCBI
21	Wang YN, Zeng ZL, Lu J, Wang Y, Liu ZX, He MM, Zhao Q, Wang ZX, Li T, Lu YX, et al: CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene. 37:6025–6040. 2018. View Article : Google Scholar : PubMed/NCBI
22	Lesuffleur T, Violette S, Vasile-Pandrea I, Dussaulx E, Barbat A, Muleris M and Zweibaum A: Resistance to high concentrations of methotrexate and 5-fluorouracil of differentiated HT-29 colon-cancer cells is restricted to cells of enterocytic phenotype. Int J Cancer. 76:383–392. 1998. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 205:275–292. 2005. View Article : Google Scholar : PubMed/NCBI
25	Xia H, Ooi LL and Hui KM: MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
26	Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE and Lothe RA: Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2:e712013. View Article : Google Scholar : PubMed/NCBI
27	van Boxtel R, Kuiper RV, Toonen PW, van Heesch S, Hermsen R, de Bruin A and Cuppen E: Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency. Am J Pathol. 179:1616–1622. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhu M, Xu Y, Ge M, Gui Z and Yan F: Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell proliferation and apoptosis. Cancer Sci. 106:833–839. 2015. View Article : Google Scholar : PubMed/NCBI
29	Wang M, Gao Q, Chen Y, Li Z, Yue L and Cao Y: PAK4, a target of miR-9-5p, promotes cell proliferation and inhibits apoptosis in colorectal cancer. Cell Mol Biol Lett. 24:582019. View Article : Google Scholar : PubMed/NCBI
30	Ahmed SM, Ramani PD, Wong SQR, Zhao X, Ivanyi-Nagy R, Leong TC, Chua C, Li Z, Hentze H, Tan IB, et al: The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity. PLoS One. 14:e02156962019. View Article : Google Scholar : PubMed/NCBI
31	Dangi-Garimella S, Sahai V, Ebine K, Kumar K and Munshi HG: Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PLoS One. 8:e645662013. View Article : Google Scholar : PubMed/NCBI
32	Zhao X, Peter S, Dröge P and Yan J: Oncofetal HMGA2 effectively curbs unconstrained (+) and (−) DNA supercoiling. Sci Rep. 7:84402017. View Article : Google Scholar : PubMed/NCBI
33	Tsavaris N, Lazaris A, Kosmas C, Gouveris P, Kavantzas N, Kopterides P, Papathomas T, Agrogiannis G, Zorzos H, Kyriakou V and Patsouris E: Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 64:391–398. 2009. View Article : Google Scholar : PubMed/NCBI